



NDA 204447

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Takeda Pharmaceuticals USA, Inc.
Attention: Joanna Sambor, M.S.
Director, Regulatory Affairs
One Takeda Parkway
Deerfield, IL 60015

Dear Ms. Sambor:

Please refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for Brintellix (vortioxetine) Tablets, which was approved on September 30, 2013.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for PMR 2084-1, which was deferred until February 28, 2015. Therefore, we are hereby notifying you that due to your failure to submit either a pediatric assessment or a request for a deferral extension, you are not in compliance with federal law.

Under the provisions of title V, section 505, of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a “**DEFERRAL EXTENSION REQUESTED**” in your response.

In accordance with FDASIA, FDA will post this letter and your response on the website located at <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm343203.htm> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a “**RESPONSE TO PREA NON-COMPLIANCE LETTER.**” To facilitate our review, submit this information to your NDA with a cross-reference letter to the IND to which your protocol has been submitted. In addition, send a copy of the cover letter to CDER’s Pediatric and Maternal Health Staff.

If you have any questions, call Hiren Patel, Regulatory Project Manager, at 301-796-2087.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
CAPT, USPHS
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
03/10/2015